References
- Cahill K, Stead LF, Lancaster T. (2012). Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 4:CD006103.
- Ebbert JO, Wyatt KD, Hays JT, et al. (2010). Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence 4:355–62.
- Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. (1991). The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86:1119–27.
- Jeong SH, Newcombe D, Sheridan J, Tingle M. (2015). Pharmacokinetics of cytisine, an alpha beta nicotinic receptor partial agonist, in healthy smokers following a single dose. Drug Test Anal 7:475-82.
- Jeong SH, Sheridan J, Newcombe D, Tingle M. (2018). Plasma concentrations of cytisine, a commercially available plant-based alkaloid, in healthy adult smokers taking recommended doses for smoking cessation. Xenobiotica 48:1245–48.
- Prochaska JJ, Das S, Benowitz NL. (2013). Cytisine, the world's oldest smoking cessation aid. BMJ 347:f5198.
- Tutka P, Zatonski W. (2006). Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep 58:777–98.
- Vinnikov D, Brimkulov N, Burjubaeva A. (2008). A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. J Smok Cessat 3:57–62.
- Walker N, Bullen C, Barnes J, et al. (2016). Getting cytisine licensed for use world-wide: a call to action: editorial. Addiction 111:1895–98.
- Walker N, Howe C, Glover M, et al. (2014). Cytisine versus nicotine for smoking cessation. N Engl J Med 371:2353–62.
- West R, Zatonski W, Cedzynska M, et al. (2011). Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 365:1193–200.